Enlivex Therapeutics (NASDAQ:ENLV) Rating Lowered to Hold at Zacks Investment Research

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Enlivex Therapeutics in a research note on Tuesday, October 5th.

Shares of Enlivex Therapeutics stock opened at $9.02 on Tuesday. The stock has a market capitalization of $165.17 million, a price-to-earnings ratio of -9.49 and a beta of 1.25. Enlivex Therapeutics has a 1-year low of $7.20 and a 1-year high of $29.40. The firm’s 50-day moving average price is $10.63 and its two-hundred day moving average price is $9.89.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Monday, August 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.09. As a group, equities analysts expect that Enlivex Therapeutics will post -0.86 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise acquired a new position in Enlivex Therapeutics during the second quarter worth $89,000. Jane Street Group LLC purchased a new stake in shares of Enlivex Therapeutics in the first quarter valued at about $123,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Enlivex Therapeutics in the first quarter valued at about $144,000. Goldman Sachs Group Inc. bought a new position in Enlivex Therapeutics during the first quarter valued at about $144,000. Finally, Morgan Stanley grew its position in Enlivex Therapeutics by 453.5% during the first quarter. Morgan Stanley now owns 15,531 shares of the company’s stock valued at $172,000 after buying an additional 12,725 shares during the period. 6.27% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders.

Recommended Story: VIX – Volatility Index

Get a free copy of the Zacks research report on Enlivex Therapeutics (ENLV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.